BRAINSWAY LTD/S (NASDAQ:BWAY) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of BRAINSWAY LTD/S (NASDAQ:BWAY) from a sell rating to a hold rating in a research note released on Monday morning, Zacks.com reports.

According to Zacks, “BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. “

BWAY has been the topic of several other research reports. CIBC initiated coverage on BRAINSWAY LTD/S in a report on Monday, May 13th. They set an outperform rating on the stock. Oppenheimer initiated coverage on BRAINSWAY LTD/S in a report on Monday, May 13th. They set an outperform rating and a $17.00 target price on the stock. LADENBURG THALM/SH SH initiated coverage on BRAINSWAY LTD/S in a report on Monday, May 13th. They set a buy rating and a $19.00 target price on the stock. Cantor Fitzgerald initiated coverage on BRAINSWAY LTD/S in a report on Monday, May 13th. They set an overweight rating and a $17.00 target price on the stock. Finally, Raymond James initiated coverage on BRAINSWAY LTD/S in a report on Monday, May 13th. They set an outperform rating and a $14.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $15.80.

Shares of BRAINSWAY LTD/S stock opened at $10.05 on Monday. The firm has a 50-day moving average price of $9.93. BRAINSWAY LTD/S has a one year low of $8.00 and a one year high of $12.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.33 and a current ratio of 1.33.

BRAINSWAY LTD/S (NASDAQ:BWAY) last issued its quarterly earnings results on Wednesday, May 29th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.00 million. Analysts predict that BRAINSWAY LTD/S will post -0.43 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. bought a new stake in BRAINSWAY LTD/S during the second quarter worth about $157,000. Noked Capital LTD bought a new stake in BRAINSWAY LTD/S during the second quarter worth about $572,000. ARK Investment Management LLC bought a new stake in BRAINSWAY LTD/S during the second quarter worth about $863,000. Finally, Delek Group Ltd. bought a new stake in BRAINSWAY LTD/S during the second quarter worth about $3,176,000. Institutional investors and hedge funds own 3.64% of the company’s stock.

About BRAINSWAY LTD/S

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Read More: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on BRAINSWAY LTD/S (BWAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BRAINSWAY LTD/S (NASDAQ:BWAY)

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.